MENU
+Compare
GLYC
Stock ticker: NASDAQ
AS OF
Apr 2, 04:59 PM (EDT)
Price
$0.21
Change
+$0.01 (+5.00%)
Capitalization
13.53M

GLYC GlycoMimetics Forecast, Technical & Fundamental Analysis

GlycoMimetics Inc is a clinical-stage biotechnology company... Show more

Industry: #Biotechnology
GLYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for GLYC with price predictions
Apr 01, 2025

GLYC's RSI Indicator is sitting in oversold zone for 2 days

It is expected that a price bounce should occur soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GLYC advanced for three days, in of 246 cases, the price rose further within the following month. The odds of a continued upward trend are .

GLYC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 25, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on GLYC as a result. In of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for GLYC turned negative on March 25, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .

GLYC moved below its 50-day moving average on March 21, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for GLYC crossed bearishly below the 50-day moving average on March 07, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLYC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for GLYC entered a downward trend on April 01, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GLYC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.546) is normal, around the industry mean (13.458). P/E Ratio (0.000) is within average values for comparable stocks, (64.587). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.867). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. GLYC's P/S Ratio (2000.000) is slightly higher than the industry average of (251.391).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLYC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
GLYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

GLYC is expected to report earnings to fall 29.03% to -10 cents per share on November 29

GlycoMimetics GLYC Stock Earnings Reports
Q3'24
Est.
$-0.11
Q2'24
Est.
$-0.16
Q1'24
Missed
by $0.01
Q4'23
Beat
by $0.01
Q3'23
Est.
$-0.14
The last earnings report on August 01 showed earnings per share of -15 cents, beating the estimate of -15 cents. With 215.84K shares outstanding, the current market capitalization sits at 13.53M.
A.I. Advisor
published General Information

General Information

a developer of drugs to treat inflammatory diseases and cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
9708 Medical Center Drive
Phone
+1 240 243-1201
Employees
35
Web
https://www.glycomimetics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HIMS31.051.50
+5.08%
Hims & Hers Health
USEA1.36N/A
N/A
United Maritime Corp
PRSU35.39N/A
N/A
Pursuit Attractions and Hospitality Inc
DG87.60-0.33
-0.38%
Dollar General Corp
KNDI1.37-0.05
-3.52%
Kandi Technologies Group

GLYC and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, GLYC has been closely correlated with LYRA. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if GLYC jumps, then LYRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLYC
1D Price
Change %
GLYC100%
-4.24%
LYRA - GLYC
76%
Closely correlated
-4.91%
EYPT - GLYC
46%
Loosely correlated
-6.83%
AXON - GLYC
36%
Loosely correlated
+2.90%
IONS - GLYC
35%
Loosely correlated
-9.65%
MDGL - GLYC
34%
Loosely correlated
-2.19%
More

Groups containing GLYC

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLYC
1D Price
Change %
GLYC100%
-4.24%
GLYC
(2 stocks)
94%
Closely correlated
+0.56%